Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
28-day randomized double-blind placebo-controlled study of SB-681323 in COPD
2004-002769-18Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing SB-681323 7.5 mg per day with Placebo (2 arms). Primary endpoints: Safety and tolerability of SB-681323 over 28 days, Pulmonary anti-inflammatory activity of SB-681323 and 1 more. Started Feb 2005; status: completed.
02
Drugs
dilmapimod
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2004-002769-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002769-18.